EMA Recommends Approval for New Pancreatic Cancer Drug, Oral GLP-1 for Weight Management, and Achondroplasia Treatment

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued positive opinions for several new medicines. These include Rasonque (daraxonrasib) for adults with metastatic pancreatic adenocarcinoma who have failed previous therapies, Foundayo (orforglipron), an oral GLP-1 receptor agonist for weight management and type 2 diabetes, and Yuviwel (navepegritide) for the treatment of achondroplasia in children. These recommendations were part of the CHMP's October 2026 meeting highlights.